• Tech
• Gadgets
• Mobile
• Enterprise
• CrunchBase
• More
  • Beta Invites
  • Elevator Pitches
  • Gillmor Gang
  • Podcasts
  • TechCrunch50
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Biolex Therapeutics

edit

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Milestones

edit

• 
  Biolex Therapeutics received $60M in Series D funding. (10/6/08)
  Posted 6/22/09 at 11:58am
• 
  Biolex Therapeutics added Jan Turek as President and CEO.
  Posted 6/22/09 at 11:58am

Videos

Screenshots

edit

Above: Biolex Therapeutics Screenshot -- #1
Uploaded: 6/22/09

Sources

1. Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C (mitsuiventures.com) [edit]